Intellia Therapeutics Inc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/3/2026)
| Balance Sheet | Total Assets | 842,127,000.00 | ROE | 79.73 % |
| Balance Sheet | Total Equity | 671,394,000.00 | ROA | -49.01 % |
| Cashflow | Capital Expenditures | -5,778,000.00 | P/FCF | -3.13 |
| Cashflow | Free Cash Flow | -395,865,000.00 | – | – |
| Cashflow | Operating Cash Flow | -394,736,000.00 | P/CF | -3.14 |
| Income | Earnings per Share (diluted) | -3.81 | Div. Yield | – |
| Income | Net Income | -412,694,000.00 | P/E | -2.98 |
| Income | Shares Outstanding | 108,376,000.00 | P/B | 1.85 |
| Income | Total Revenue | 67,671,000.00 | P/S | 18.31 |
Ratios calculated on: 10/14/2026
Company Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.intelliatx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more